131411 20241125101139.0 doi 10.1038/s41598-023-50537-y sideral 136838 ART-2023-136838 eng Martínez-Domínguez, Samuel J. Universidad de Zaragoza Unravelling the cellular response to the SARS-COV-2 vaccine in inflammatory bowel disease patients on biologic drugs 2023 Access copy available to the general public Unrestricted Suboptimal vaccine response is a significant concern in patients with Inflammatory Bowel Disease (IBD) receiving biologic drugs. This single-center observational study involved 754 patients with IBD. In Phase I (October 2020-April 2021), 754 IBD participants who had not previously received the SARS-CoV-2 vaccine, underwent blood extraction to assess the seroprevalence of SARS-CoV-2 infection and IBD-related factors. Phase II (May 2021-October 2021) included a subgroup of 52 IBD participants with confirmed previous SARS-CoV-2 infection, who were studied for humoral and cellular response to the SARS-CoV-2 vaccine. In Phase I, treatment with anti-TNF was associated with lower rates of seroconversion (aOR 0.25 95% CI [0.10–0.61]). In Phase II, a significant increase in post-vaccination IgG levels was observed regardless of biologic treatment. However, patients treated with anti-TNF exhibited significantly lower IgG levels compared to those without IBD therapy (5.32 ± 2.47 vs. 7.99 ± 2.59 U/ml, p = 0.042). Following vaccination, a lymphocyte, monocyte, and NK cell activation pattern was observed, with no significant differences between patients receiving biologic drugs and those without IBD treatment. Despite lower seroprevalence and humoral response to the SARS-CoV-2 vaccine in patients treated with anti-TNF, the cellular response to the vaccine did not differ significantly from that patients without IBD therapy. info:eu-repo/grantAgreement/ES/AEI/PID2020-113963RB-I00 info:eu-repo/grantAgreement/ES/DGA-FEDER/B29-17R info:eu-repo/grantAgreement/ES/ISCIII/CB21-13-100087 info:eu-repo/semantics/openAccess by http://creativecommons.org/licenses/by/3.0/es/ 3.8 2023 MULTIDISCIPLINARY SCIENCES 25 / 134 = 0.187 2023 Q1 T1 0.9 2023 Multidisciplinary 2023 Q1 7.5 2023 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion García-Mateo, Sandra Universidad de Zaragoza Sainz-Arnal, Pilar Martínez-García, Javier Gallego-Llera, Beatriz Lozano-Limones, María Jesús Hidalgo, Sandra Gargallo-Puyuelo, Carla J. Universidad de Zaragoza (orcid)0000-0002-3545-2707 Latre-Santos, Marta Nocito-Colon, Maria Mercedes Lourdes Martínez-Lostao, Luis Universidad de Zaragoza (orcid)0000-0003-3043-147X Refaie, Engy Arroyo-Villarino, Maria Teresa Universidad de Zaragoza (orcid)0000-0002-4991-8715 del Rio-Nechaevsky, Marcela Ramirez-Labrada, Ariel (orcid)0000-0002-3888-7036 Pardo, Julián Gomollón, Fernando Universidad de Zaragoza (orcid)0000-0003-0076-3529 Baptista, Pedro M. (orcid)0000-0002-8969-7726 1007 610 Universidad de Zaragoza Dpto. Medicina, Psiqu. y Derm. Area Medicina 1011 566 Universidad de Zaragoza Dpto. Microb.Ped.Radio.Sal.Pú. Área Inmunología 13, 1 (2023), 23061 [11 pp.] Sci. rep. (Nat. Publ. Group) Scientific reports (Nature Publishing Group) 2045-2322 2967240 http://zaguan.unizar.es/record/131411/files/texto_completo.pdf Versión publicada 2481974 http://zaguan.unizar.es/record/131411/files/texto_completo.jpg?subformat=icon icon Versión publicada oai:zaguan.unizar.es:131411 articulos driver 2024-11-22-12:02:09 ARTICLE